Pifithrin
{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464206558
| Name = Pifithrin-α
| ImageFile = Pifithrin.PNG
| ImageName =
| IUPACName = 2-amino-3-[2-(4-methylphenyl)-2-oxoethyl]-2,3,4,5,6,7-hexahydro-1,3-benzothiazol-2-ylium bromide
|Section1={{Chembox Identifiers
| index_label = α
| index1_label = β
| InChI = 1/C16H19N2OS.BrH/c1-11-6-8-12(9-7-11)14(19)10-18-13-4-2-3-5-15(13)20-16(18)17;/h6-9H,2-5,10,17H2,1H3;1H/q+1;/p-1
| InChIKey = KXMMOFYVZLFBEG-REWHXWOFAW
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 556353
| ChEMBL1 = 193504
| ChEBI = 93168
| ChEBI1 = 92551
| KEGG1 = C11571
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H18N2OS.BrH/c1-11-6-8-12(9-7-11)14(19)10-18-13-4-2-3-5-15(13)20-16(18)17;/h6-9,17H,2-5,10H2,1H3;1H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HAGVCKULCLQGRF-UHFFFAOYSA-N
| InChI1=1S/C16H16N2S/c1-11-6-8-12(9-7-11)13-10-18-14-4-2-3-5-15(14)19-16(18)17-13/h6-10H,2-5H2,1H3
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 63208-82-2
| CASNo1_Ref = {{cascite|correct|CAS}}
| CASNo1 = 60477-34-1
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID =21106463
| PubChem = 4817
| PubChem1 = 443278
| DTXSID = DTXSID10432994
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D213B92S1Y
| UNII1_Ref = {{fdacite|correct|FDA}}
| UNII1 = 45I8QO7K37
| SMILES = CC1=CC=C(C=C1)C(=O)CN2C3=C(CCCC3)SC2=N
| SMILES1 = CC1=CC=C(C=C1)C2=CN3C4=C(CCCC4)SC3=N2
| SMILES5 = [Br-].Cc1ccc(cc1)C(=O)Cn2[c+](N)sc3CCCCc23
}}
|Section2={{Chembox Properties
| Formula = C16H19BrN2OS
| MolarMass = 367.30 g/mol
| Density =
| MeltingPtC = 192.1
| BoilingPt =
}}
}}
Pifithrin-α (chemical name 2-(2-Imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone hydrobromide{{Cite web |title=sigmaaldrich.com |url=https://www.sigmaaldrich.com/GB/en/product/sigma/p4359 |website=Merck}}) is a chemical compound which acts as an inhibitor of the tumour-suppressing and epileptogenic protein p53.George SL, Parmar V, Lorenzi F, Marshall LV, Jamin Y, Poon E, Angelini P, Chesler L. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. J Exp Clin Cancer Res. 2020 May 6;39(1):78. {{doi|10.1186/s13046-020-01582-2}} {{PMID|32375866}}Gupta V, Singh S, Singh TG. Pervasive expostulation of p53 gene promoting the precipitation of neurogenic convulsions: A journey in therapeutic advancements. Eur J Pharmacol. 2024 Nov 15;983:176990. {{doi|10.1016/j.ejphar.2024.176990}} {{PMID|39251181}} It has a molecular weight of 367.30 and is soluble in DMSO up to 20 mg/mL. Its melting point is 192.1-192.5 °C.